Cytokinetics heart disease drug meets main goals in late-stage study
May 5 (Reuters) - Cytokinetics CYTK.O said on Tuesday its experimental drug to treat a type of heart disease met the main goals in a late-stage trial. (Reporting by Sneha S K; Editing by Devika Syamnath) ((Sneha.SK@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech